Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Videos|August 18, 2022
Dr. Jang on current state of immunotherapy in advanced GU cancers
Author(s)Urology Times staff
Advertisement
Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses progress and unmet needs with immunotherapy for the treatment of patients with genitourinary cancers.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5